- Home
- PII vs MIRM Comparison
PII vs MIRM Comparison
Compare PII & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PII
- MIRM
- Stock Information
- Founded
- PII 1954
- MIRM 2018
- Country
- PII United States
- MIRM United States
- Employees
- PII N/A
- MIRM N/A
- Industry
- PII Recreational Games/Products/Toys
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- PII Consumer Discretionary
- MIRM Health Care
- Exchange
- PII Nasdaq
- MIRM Nasdaq
- Market Cap
- PII 3.7B
- MIRM 3.7B
- IPO Year
- PII 1987
- MIRM 2019
- Fundamental
- Price
- PII $66.84
- MIRM $72.69
- Analyst Decision
- PII Hold
- MIRM Strong Buy
- Analyst Count
- PII 11
- MIRM 11
- Target Price
- PII $52.80
- MIRM $82.82
- AVG Volume (30 Days)
- PII 834.4K
- MIRM 593.2K
- Earning Date
- PII 10-28-2025
- MIRM 11-04-2025
- Dividend Yield
- PII 4.04%
- MIRM N/A
- EPS Growth
- PII N/A
- MIRM N/A
- EPS
- PII N/A
- MIRM N/A
- Revenue
- PII $7,076,200,000.00
- MIRM $471,794,000.00
- Revenue This Year
- PII N/A
- MIRM $53.14
- Revenue Next Year
- PII $1.02
- MIRM $19.83
- P/E Ratio
- PII N/A
- MIRM N/A
- Revenue Growth
- PII N/A
- MIRM 53.66
- 52 Week Low
- PII $30.92
- MIRM $36.88
- 52 Week High
- PII $75.25
- MIRM $78.55
- Technical
- Relative Strength Index (RSI)
- PII 56.22
- MIRM 55.55
- Support Level
- PII $59.63
- MIRM $71.04
- Resistance Level
- PII $67.80
- MIRM $73.50
- Average True Range (ATR)
- PII 2.38
- MIRM 2.74
- MACD
- PII 0.19
- MIRM 0.33
- Stochastic Oscillator
- PII 87.38
- MIRM 78.35
About PII Polaris Inc.
Polaris designs and manufactures off-road vehicles, including all-terrain vehicles and side-by-side vehicles for recreational and utility purposes, snowmobiles, and on-road vehicles, including motorcycles, along with the related replacement parts, garments, and accessories. The firm entered the marine market after acquiring Boat Holdings in 2018, offering exposure to another segment of the outdoor lifestyle market. Polaris products are retailed through more than 2,500 dealers in North America and 1,500 international dealers as well as more than 25 subsidiaries and 90 distributors in more than 100 countries outside North America.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.